Fesoterodine (Toviaz®)

Usual Dosing (Adults)

INDICATIONS AND USAGE
Toviaz is a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. (1)

DOSAGE AND ADMINISTRATION-------------------------------------
The recommended starting dose of Toviaz is 4 mg once daily. Based upon individual response and tolerability, the dose may be increased to 8 mg once daily. (2)

The daily dose of Toviaz should not exceed 4 mg in the following populations:

-Patients with severe renal impairment (CLCR <30 mL/min)
-Patients taking potent CYP3A4 inhibitors, such as ketoconazole, itraconazole, and clarithromycin.

Toviaz is not recommended for use in patients with severe hepatic impairment (Child-Pugh C).

Toviaz should be taken with liquid and swallowed whole. Toviaz can be administered with or without food, and should not be chewed, divided, or crushed.

DOSAGE FORMS AND STRENGTHS
Toviaz 4 mg extended-release tablets are light blue, oval, biconvex, film-coated, and engraved with "FS" on one side.

Toviaz 8 mg extended-release tablets are blue, oval, biconvex, film-coated, and engraved with "FT" on one side.

Renal Dosing

The daily dose of Toviaz should not exceed 4 mg in patients with severe renal impairment (CLCR <30 mL/min).

Hemodialysis

See above.

Reference(s)

National Institutes of Health, U.S. National Library of Medicine, DailyMed Database.
Provides access to the latest drug monographs submitted to the Food and Drug Administration (FDA). Please review the latest applicable package insert for additional information and possible updates. A local search option of this data can be found here.